Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Muggia

Showing results (11-20 of 95) with videos related to

Pageof 10
Sort By:
Expert Review of Anticancer Therapy|October 14, 2005
Investigational agents for epithelial ovarian cancerFranco Muggia, Rebecca Kosloff
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
History of intraperitoneal platinum drug delivery for ovarian cancer and its future applicationsFranco Muggia, Andrea Bonetti
Expert Opinion on Drug Safety|April 23, 2014
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indicationsDavid Kudlowitz, Franco Muggia
Ecancermedicalscience|March 28, 2019
Women's cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeuticsPooja Murthy, Franco Muggia
Clinical Breast Cancer|July 22, 2008
Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanesEleni Andreopoulou, Franco Muggia
Anti-Cancer Drugs|December 5, 2013
Clinical features of taxane neuropathyDavid Kudlowitz, Franco Muggia
Anti-Cancer Drugs|December 31, 2013
Novel taxanesFranco Muggia, David Kudlowitz
Gynecologic Oncology Reports|September 14, 2018
Platinum type is key in determining degree of neuropathyFranco Muggia, David Kudlowitz
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2013
Defining risks of taxane neuropathy: insights from randomized clinical trialsDavid Kudlowitz, Franco Muggia
Oncology (Williston Park, N.Y.)|August 6, 2013
HE4: another 'player' in the epithelial tumor marker arena?Eleonora Teplinsky, Franco Muggia
Pageof 10

Showing results (11-20 of 95) with videos related to

Sort By:
Pageof 10
Expert Review of Anticancer Therapy|October 14, 2005
Investigational agents for epithelial ovarian cancerFranco Muggia, Rebecca Kosloff
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
History of intraperitoneal platinum drug delivery for ovarian cancer and its future applicationsFranco Muggia, Andrea Bonetti
Expert Opinion on Drug Safety|April 23, 2014
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indicationsDavid Kudlowitz, Franco Muggia
Ecancermedicalscience|March 28, 2019
Women's cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeuticsPooja Murthy, Franco Muggia
Clinical Breast Cancer|July 22, 2008
Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanesEleni Andreopoulou, Franco Muggia
Anti-Cancer Drugs|December 5, 2013
Clinical features of taxane neuropathyDavid Kudlowitz, Franco Muggia
Anti-Cancer Drugs|December 31, 2013
Novel taxanesFranco Muggia, David Kudlowitz
Gynecologic Oncology Reports|September 14, 2018
Platinum type is key in determining degree of neuropathyFranco Muggia, David Kudlowitz
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2013
Defining risks of taxane neuropathy: insights from randomized clinical trialsDavid Kudlowitz, Franco Muggia
Oncology (Williston Park, N.Y.)|August 6, 2013
HE4: another 'player' in the epithelial tumor marker arena?Eleonora Teplinsky, Franco Muggia
Pageof 10